HK1099244A1 - Tetrahydroindolone derivatives for treatment of neurological conditions - Google Patents
Tetrahydroindolone derivatives for treatment of neurological conditionsInfo
- Publication number
- HK1099244A1 HK1099244A1 HK07104686.4A HK07104686A HK1099244A1 HK 1099244 A1 HK1099244 A1 HK 1099244A1 HK 07104686 A HK07104686 A HK 07104686A HK 1099244 A1 HK1099244 A1 HK 1099244A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- neurological conditions
- tetrahydroindolone derivatives
- tetrahydroindolone
- derivatives
- Prior art date
Links
- YJJUTLWYXYQJNJ-UHFFFAOYSA-N 1,3,3a,4-tetrahydroindol-2-one Chemical class C1C=CC=C2NC(=O)CC21 YJJUTLWYXYQJNJ-UHFFFAOYSA-N 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50569203P | 2003-09-25 | 2003-09-25 | |
| PCT/US2004/031743 WO2005030148A2 (en) | 2003-09-25 | 2004-09-27 | Tetrahydroindolone derivatives for treatment of neurological conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1099244A1 true HK1099244A1 (en) | 2007-08-10 |
Family
ID=34393056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK07104686.4A HK1099244A1 (en) | 2003-09-25 | 2007-05-02 | Tetrahydroindolone derivatives for treatment of neurological conditions |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7795266B2 (xx) |
| EP (1) | EP1715921B1 (xx) |
| JP (1) | JP4964593B2 (xx) |
| CA (1) | CA2580730C (xx) |
| HK (1) | HK1099244A1 (xx) |
| WO (1) | WO2005030148A2 (xx) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6759427B2 (en) * | 2001-04-20 | 2004-07-06 | Spectrum Pharmaceuticals, Inc. | Synthesis and methods of use of tetrahydroindolone analogues and derivatives |
| WO2007101156A1 (en) * | 2006-02-27 | 2007-09-07 | Serenex, Inc. | Cyclohexylamino, benzene, pyridine, and pyridazine derivatives |
| WO2008024980A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives |
| EP2219648A4 (en) * | 2007-11-09 | 2010-11-03 | Cenomed Biosciences Llc | TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS |
| US20090264443A1 (en) * | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3621027A (en) | 1968-03-18 | 1971-11-16 | Endo Lab | 1-aminoalkyl-2,6-diaryl 4,5,6,7 tetrahydro-4-oxindales |
| US4260762A (en) | 1979-09-10 | 1981-04-07 | Hoffmann-La Roche Inc. | Octahydro-1H-pyrrolo[2,3-g]isoquinolines |
| US4442291A (en) | 1979-09-10 | 1984-04-10 | Hoffmann-La Roche Inc. | 1,2,3,4,4a,7-Hexahydro-6,8-dimethoxy-2-methyl isoquinoline |
| US4349678A (en) | 1979-09-10 | 1982-09-14 | Hoffmann-La Roche Inc. | Octahydro-2-methyl-isoquinoline-6,8-dione |
| SE9103752D0 (sv) | 1991-12-18 | 1991-12-18 | Astra Ab | New compounds |
| PL182285B1 (pl) | 1994-08-12 | 2001-12-31 | Lilly Co Eli | Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL |
| US5661184A (en) | 1994-08-12 | 1997-08-26 | Eli Lilly And Company | Psychiatric agents |
| US5717109A (en) | 1994-09-08 | 1998-02-10 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| WO1996040043A2 (en) | 1995-06-06 | 1996-12-19 | Cocensys, Inc. | Neuroactive steroids of the androstane and pregnane series |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| ZA969485B (en) | 1995-11-16 | 1998-05-12 | Lilly Co Eli | Excitatory amino acid receptor antagonists. |
| FR2742052B1 (fr) | 1995-12-12 | 1998-04-10 | Esteve Labor Dr | Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports |
| CN1219878A (zh) | 1996-03-25 | 1999-06-16 | 伊莱利利公司 | 治疗疼痛的方法 |
| EP0906104A4 (en) | 1996-03-25 | 2003-12-10 | Lilly Co Eli | PAIN TREATMENT PROCESS |
| CA2285192A1 (en) | 1997-04-07 | 1998-10-15 | Smriti Iyengar | Pharmacological agents |
| JP2002505288A (ja) | 1998-03-02 | 2002-02-19 | コセンシス，インコーポレイテッド | 置換キナゾリンおよびアナログならびにそれらの使用 |
| GB9812038D0 (en) | 1998-06-04 | 1998-07-29 | Merck Sharp & Dohme | Therapeutic compound |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| US6680332B1 (en) | 1999-06-04 | 2004-01-20 | Euro-Celtique S.A. | Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA |
| CN1372546A (zh) | 1999-08-31 | 2002-10-02 | 神经原公司 | 稠合的吡咯甲酰胺:gaba脑受体的配体 |
| US7146209B2 (en) | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
| US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
| US20020040032A1 (en) | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for stimulation of synthesis of synaptophysin in the central nervous system |
| WO2002004449A2 (en) | 2000-07-07 | 2002-01-17 | Neotherapeutics, Inc. | Methods for treatment of conditions affected by activity of multidrug transporters |
| AU2001273212A1 (en) | 2000-07-07 | 2002-01-21 | Neotherapeutics, Inc. | Methods for treatment of drug-induced peripheral neuropathy and related conditions |
| US20020040031A1 (en) | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system |
| MXPA03001421A (es) | 2000-08-14 | 2004-01-26 | Johnson & Johnson | Pirazoles sustituidos. |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| WO2002058736A2 (en) | 2000-12-12 | 2002-08-01 | Neotherapetics, Inc. | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis |
| US6770638B2 (en) | 2001-04-20 | 2004-08-03 | Spectrum Pharmaceuticals, Inc. | Tetrahydroindolone and purine derivatives linked to arylpiperazines |
| US6759427B2 (en) | 2001-04-20 | 2004-07-06 | Spectrum Pharmaceuticals, Inc. | Synthesis and methods of use of tetrahydroindolone analogues and derivatives |
| CA2450245A1 (en) | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| CA2455987C (en) * | 2001-07-30 | 2010-06-29 | Neotherapeutics, Inc. | Tetrahydroindolone and purine derivatives linked to arylpiperazines |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20050107439A1 (en) | 2003-11-10 | 2005-05-19 | Helton David R. | Composition and method for treating emesis |
| US20060025420A1 (en) | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| JP2008515971A (ja) | 2004-10-12 | 2008-05-15 | デコード ジェネティクス イーエイチエフ | 閉塞性動脈疾患のためのスルホンアミドぺリ置換二環式化合物 |
-
2004
- 2004-09-27 EP EP04785168.8A patent/EP1715921B1/en not_active Not-in-force
- 2004-09-27 WO PCT/US2004/031743 patent/WO2005030148A2/en active Application Filing
- 2004-09-27 JP JP2006528303A patent/JP4964593B2/ja active Active
- 2004-09-27 CA CA2580730A patent/CA2580730C/en active Active
- 2004-09-27 US US10/595,219 patent/US7795266B2/en active Active
-
2007
- 2007-05-02 HK HK07104686.4A patent/HK1099244A1/xx unknown
-
2010
- 2010-08-06 US US12/852,251 patent/US8598180B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP4964593B2 (ja) | 2012-07-04 |
| EP1715921A2 (en) | 2006-11-02 |
| EP1715921A4 (en) | 2009-07-15 |
| WO2005030148A3 (en) | 2005-06-30 |
| US20100305141A1 (en) | 2010-12-02 |
| US7795266B2 (en) | 2010-09-14 |
| WO2005030148A2 (en) | 2005-04-07 |
| US8598180B2 (en) | 2013-12-03 |
| CA2580730A1 (en) | 2005-04-07 |
| JP2007523886A (ja) | 2007-08-23 |
| EP1715921B1 (en) | 2013-04-24 |
| CA2580730C (en) | 2015-01-13 |
| US20070208030A1 (en) | 2007-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1078858A1 (en) | Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders | |
| EG25204A (en) | Benzo diazepine derivatives for the treatment of neurological disorders | |
| EG24420A (en) | Treatment of ophthalmic conditions | |
| EP1617844A4 (en) | TREATMENT OF NEUROLOGICAL DISEASES | |
| IL175712A0 (en) | N-arylhydrazine derivatives for seed treatment | |
| GB0312832D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
| HK1090634A1 (en) | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases | |
| GB2415378B (en) | Treatment of neurodegenerative conditions | |
| GB2422373B (en) | Treatment of neurodegenerative conditions | |
| GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
| EP1680145A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| EP1651237A4 (en) | METHOD FOR THE TREATMENT OF DERMATOLOGICAL ILLNESSES | |
| HK1099244A1 (en) | Tetrahydroindolone derivatives for treatment of neurological conditions | |
| GB0306309D0 (en) | Method of treatment | |
| GB0302572D0 (en) | Method of treatment | |
| GB0300783D0 (en) | Treatment of neurodegenerative conditions | |
| AU2004901652A0 (en) | Treatment of neurological conditions | |
| PT1706094T (pt) | Tratamento de condições oftalmológicas | |
| GB2442164B (en) | Treatment of neurodegenerative conditions | |
| GB0724618D0 (en) | Treatment of neurodegenerative conditions | |
| GB0319358D0 (en) | Treatment of neurodegenerative conditions | |
| SI1485057T1 (sl) | Derivati azaspiro spojin za zdravljenje bolecine | |
| IL173359A0 (en) | Compounds useful for treating neurological disorders | |
| GB0312840D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
| GB0312842D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases |